GlassScriptPhysician profile
Amelia Maass
NPI 1366488348
$6,681.14
in general payments reported to CMS, 2019-2025
50 companies · $1,382 in 2025
The $1,382 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,283 · 2022: $1,142 · 2023: $1,526 · 2024: $1,349 · 2025: $1,382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,256.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,265.60 | 2021-2025 | |
| Amgen INC. | $585.83 | 2021-2025 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $474.48 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $391.77 | 2021-2025 | |
| Glaxosmithkline, LLC. | $360.33 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $346.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $331.36 | 2021-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $324.16 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Axsome Therapeutics, INC. | $222.89 | 2022-2025 | Sunosi, Auvelity |
| Merck Sharp & Dohme LLC | $204.45 | 2021-2023 | Vaxneuvance, Proquad, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.69 | 2021-2024 | Jardiance |
| Abbott Laboratories | $148.96 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $142.27 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $126.00 | 2021-2025 | Spravato, Xarelto |
| Mylan Specialty L.P. | $110.66 | 2021-2023 | Yupelri |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Maass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.